CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.
about
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatmentBioenergetic analysis of ovarian cancer cell lines: profiling of histological subtypes and identification of a mitochondria-defective cell line.Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.Update on the utility of prognostic biomarkers in ovarian cancer.Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients.Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort StudyRecent progress in the diagnosis and treatment of ovarian cancerClinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian CancerComparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study.The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study.Clinical efficacy of serum human epididymis protein 4 as a diagnostic biomarker of ovarian cancer: A pilot study.S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types
P2860
Q26862558-C2ECE809-C669-43BD-8453-B082F9BB3D6FQ33655175-CB46C375-D356-44CA-98D2-DA7C881C2C4AQ33735170-001698D3-D0AF-4161-A6DB-7B0C751E7AD9Q34076455-B727E581-2FA7-4807-A51C-FD9311D78C36Q35694661-B2A48DFF-8831-4B49-83C8-F5011E513A09Q36482461-FEF57A7A-A34B-405C-889B-6D3FF4DB85DCQ36622857-E1AF278B-41DC-4C2A-B648-F12928683E2AQ36707873-79EBABA1-8CF7-4139-A443-B1C3DD07D60AQ36817504-279528BF-25EC-4A50-9D87-D9185F1DDDE3Q37085824-C99E8FC6-AB4C-471E-8084-BDE1989F4DDBQ37200036-420B38B7-1829-4314-8D3F-47AF5A6ACAA7Q37383301-D4A899F7-BBB7-4184-B7C4-8F8CC6D63A2AQ37612098-4DCA0817-1021-495A-A1E2-C056F749F995Q58737912-F9E40DE7-5AB5-4606-9606-E1EAC9024CDF
P2860
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CA-125 change after chemothera ...... ecologic Oncology Group study.
@en
CA-125 change after chemothera ...... ecologic Oncology Group study.
@nl
type
label
CA-125 change after chemothera ...... ecologic Oncology Group study.
@en
CA-125 change after chemothera ...... ecologic Oncology Group study.
@nl
prefLabel
CA-125 change after chemothera ...... ecologic Oncology Group study.
@en
CA-125 change after chemothera ...... ecologic Oncology Group study.
@nl
P2093
P2860
P356
P1433
P1476
CA-125 change after chemothera ...... ecologic Oncology Group study.
@en
P2093
Chunqiao Tian
David Spriggs
Deborah K Armstrong
Maurie Markman
Peter G Rose
Richard Zaino
Robert F Ozols
William P McGuire
P2860
P304
P356
10.1002/CNCR.24152
P407
P577
2009-04-01T00:00:00Z